Should you buy Perrigo Company (PRGO)?
Updated
Perrigo is a deeply discounted generic drug manufacturer trading at a forward price-to-earnings of 4.5 times and a PEG of 0.04, with analysts seeing 54% upside to target, but the company is in a confirmed death cross with declining revenue of negative 7%, no competitive moat identified, and quality scoring only 3.0 out of 10, making it a value trap candidate that must demonstrate earnings stabilization to justify the valuation.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Revenue declined by 7% year-over-year and the quality score is only 3.0 out of 10 with no competitive moat identified, a return on assets of only 1.4%, and no free cash flow margin, indicating that the core business is losing competitive ground in the generic over-the-counter pharmaceutical market. Growth breakdown | Revenue growth turns positive in at least 1 of the next 2 reported annual periods, signaling stabilization of the business. | →Stable |
| CounterGeneric pharmaceutical companies can cycle through periods of pricing pressure and product mix shifts; a favorable regulatory ruling on a new product approval could reverse the revenue trend quickly. | ||
Perrigo trades at a forward price-to-earnings of only 4.5 times with a PEG ratio of 0.04, an almost unprecedented discount to earnings growth, and analysts collectively see 54% upside to the consensus target of $14.03 from the current price of $10.70. Valuation breakdown | The stock appreciates by more than 25% toward the analyst consensus target within 12 months as the valuation gap narrows. | →Stable |
| CounterA PEG ratio of 0.04 and forward PE of 4.5 times may reflect genuine business deterioration risk; extremely cheap multiples in declining revenue businesses often signal value trap dynamics rather than undervaluation. | ||
The death cross is confirmed with the 200-day moving average declining at negative 11.9% per 30 days, one of the steepest downtrend slopes in this sector, and falling on-balance volume confirms that institutional selling has been sustained and consistent. Momentum breakdown | The 200-day moving average slope improves to above negative 5% per 30 days within 4 months, indicating that the rate of decline is at least slowing. | →Stable |
| CounterAn RSI of 52 and an improving MACD within a death cross setup can signal that the selling is exhausted; the death cross is a lagging indicator that may not predict additional significant downside. | ||
Revenue declined by 7% year-over-year and the quality score is only 3.0 out of 10 with no competitive moat identified, a return on assets of only 1.4%, and no free cash flow margin, indicating that the core business is losing competitive ground in the generic over-the-counter pharmaceutical market.
→Stable- Expectation
- Revenue growth turns positive in at least 1 of the next 2 reported annual periods, signaling stabilization of the business.
CounterGeneric pharmaceutical companies can cycle through periods of pricing pressure and product mix shifts; a favorable regulatory ruling on a new product approval could reverse the revenue trend quickly.
Perrigo trades at a forward price-to-earnings of only 4.5 times with a PEG ratio of 0.04, an almost unprecedented discount to earnings growth, and analysts collectively see 54% upside to the consensus target of $14.03 from the current price of $10.70.
→Stable- Expectation
- The stock appreciates by more than 25% toward the analyst consensus target within 12 months as the valuation gap narrows.
CounterA PEG ratio of 0.04 and forward PE of 4.5 times may reflect genuine business deterioration risk; extremely cheap multiples in declining revenue businesses often signal value trap dynamics rather than undervaluation.
The death cross is confirmed with the 200-day moving average declining at negative 11.9% per 30 days, one of the steepest downtrend slopes in this sector, and falling on-balance volume confirms that institutional selling has been sustained and consistent.
→Stable- Expectation
- The 200-day moving average slope improves to above negative 5% per 30 days within 4 months, indicating that the rate of decline is at least slowing.
CounterAn RSI of 52 and an improving MACD within a death cross setup can signal that the selling is exhausted; the death cross is a lagging indicator that may not predict additional significant downside.
▸ Show 1 more pillar▾ Show fewer
Short interest of 17% of float is flagged as justified by the data, meaning the skeptical market positioning appears supported by fundamentals rather than representing a contrarian buying opportunity at this stage.
→Stable- Expectation
- Short interest falls below 10% of float over the next 6 months, signaling that the bear thesis has lost conviction.
CounterJustified short interest can also create a powerful reversal catalyst; if Perrigo resolves a legal overhang or announces a material asset sale, a short squeeze could amplify gains significantly.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perrigo trades at a forward price-to-earnings of only 4.5 times with a PEG ratio of 0.04, an almost unprecedented discount to earnings growth, and analysts collectively see 54% upside to the consensus target of $14.03 from the current price of $10.70.
Trip ifThe stock price falls below $8 at any point over the next 12 months, indicating the value thesis is breaking down rather than recovering.
- P2Revenue declined by 7% year-over-year and the quality score is only 3.0 out of 10 with no competitive moat identified, a return on assets of only 1.4%, and no free cash flow margin, indicating that the core business is losing competitive ground in the generic over-the-counter pharmaceutical market.
Trip ifRevenue declines by more than 10% year-over-year in any reported annual period, indicating the business deterioration is accelerating.
- P3The death cross is confirmed with the 200-day moving average declining at negative 11.9% per 30 days, one of the steepest downtrend slopes in this sector, and falling on-balance volume confirms that institutional selling has been sustained and consistent.
Trip ifThe 200-day moving average slope remains below negative 10% per 30 days for more than 3 consecutive months.
- P4Short interest of 17% of float is flagged as justified by the data, meaning the skeptical market positioning appears supported by fundamentals rather than representing a contrarian buying opportunity at this stage.
Trip ifShort interest rises above 22% of float at any point over the next 6 months.
How the engine reached this verdict
TrendMatrix's engine output for Perrigo Company plc (PRGO) is SELL_IF_HOLDING with medium conviction, score 5.0/10 at $9.83. An L1 hard-floor gate blocked the positive-verdict path — Quality below minimum threshold. Co-failing gates ( MOMENTUM:1.4<4.5, DEATH_CROSS:HARD_BLOCK) reinforce the read; dimensional pillars cannot lift the engine output above the verdict floor while the L1 gate is active.
The engine's exit framework anchors to a tactical sell band near $9.83, with structural invalidation at $9.16. The asymmetric R:R against a reversal hypothesis is 6.06 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
On the bear side: Quality below floor (3.0 < 4.0). Active engine warnings: Quality below floor (3.0 < 4.0), V9 Gate Failed: MOMENTUM:1.4<4.5, V9 Gate Failed: DEATH_CROSS:HARD_BLOCK.
The dominant failed gate is momentum at 1.4 vs threshold 4.5 (with co-failures: death cross). SELL flips back toward HOLD if momentum recovers above its threshold AND a co-failing gate also clears. The strongest-cleared gate today is ASYMMETRY:3.7>=1.5.
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PRGO — 10-dimension breakdown →
Bear case
- ▸Quality below floor (3.0 < 4.0)